Johnny Kao is an Oncology physician affiliated with Good Samaritan University Hospital. OpenAlex indexes 135 publications with 3,788 citations (h-index 32); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1000 Montauk Hwy
West Islip, NY 117954927
Telephone
631-376-4047Registry record last updated 14 Feb 2013.
Clinical trials
- Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer
Sponsor: Good Samaritan Hospital Medical Center, New York
- Phase II Trial of Conventional Versus IMRT Whole Brain Radiotherapy for Brain Metastases
Sponsor: Good Samaritan Hospital Medical Center, New York
- Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Sponsor: Johnny Kao
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novocure Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year20244 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
80.8%alpha-Adrenergic Blocker80.8%Tamsulosin Hcl100%Part D≥27 patientsMetabolism & gastrointestinal
19.2%Aluminum Complex19.2%Sucralfate100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prognostic role of baseline neutrophil‑to‑lymphocyte ratio in metastatic solid tumors
Molecular and Clinical Oncology
2020 - The NEAT Predictive Model for Survival in Patients with Advanced Cancer
Cancer Research and Treatment
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Symeon Missios, MD
Good Samaritan University Hospital
Javaad Ahmad, MD
Good Samaritan University Hospital
Dilys Whyte, MD
Good Samaritan University Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”